Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma

Cancer

Volumn 117, Issue 11, 2011, Pages 2442-2451

  Baiocchi, Robert A ^a   Alinari, Lapo ^a   Lustberg, Mark E ^a   Lin, Thomas S ^a   Porcu, Pierluigi ^a   Li, Xiaobai ^a   Johnston, Jeffrey S ^a   Byrd, John C ^a   Blum, Kristie A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Bortezomib; Follicular lymphoma; Mantle cell lymphoma; Neuropathy; Rituximab

Indexed keywords

BORTEZOMIB; FC RECEPTOR IIA; PROTEASOME; RITUXIMAB;

ADRENAL INSUFFICIENCY; ADULT; AGED; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; AUTONOMIC NEUROPATHY; CANCER CELL CULTURE; CANCER RELAPSE; CANCER RESISTANCE; CELL STRAIN JEKO; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; GENETIC POLYMORPHISM; HEART DISEASE; HETEROZYGOSITY; HOMOZYGOTE; HUMAN; HUMAN CELL; ILEUS; IN VIVO STUDY; MALE; MANTLE CELL LYMPHOMA; MOTOR NEUROPATHY; MOUSE; MULTIPLE CYCLE TREATMENT; MYOSITIS; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; ORTHOSTATIC HYPOTENSION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCID MOUSE; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

BORTEZOMIB; FOLLICULAR LYMPHOMA; MANTLE CELL LYMPHOMA; NEUROPATHY; RITUXIMAB;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; MALE; MICE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEASOME INHIBITORS; PYRAZINES; RECEPTORS, IGG; RECURRENCE; TREATMENT OUTCOME;

EID: 79958764877     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25792     Document Type: Article

References (33)

1. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:667-675. (Pubitemid 46224166)
2. Orlowski RZ, Stinchombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002;20: 4420-4427. (Pubitemid 35334752)
3. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005;23:676-684. (Pubitemid 46237441)
4. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol. 2006; 24:2105-2112. (Pubitemid 46622122)
5. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20:520-525.
6. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-inde-pendent prostate cancer. J Clin Oncol. 2004;22:2108-2121. (Pubitemid 41095144)
7. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8:2505-2511. (Pubitemid 34856332)
8. Alinari L, White V, Earl C, et al. Combination bortezomib and rituximab affect multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs. 2009;1:31-40.
9. Wang M, Han XH, Zhang L, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2007;22:179-185.
10. Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and post-transcriptional levels. Clin Cancer Res. 2008;14:1561-1570. (Pubitemid 351413941)
11. Liu Q, Alinari L, Chen C-S, et al. FTY720 demonstrates promising in vitro and in vivo pre-clinical activity by down modulating cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res. 2010;16:3182-3192.
12. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Hematopoeitic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international report to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-1253. (Pubitemid 29162950)
14. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem. 2000;46:673-683. (Pubitemid 30318423)
15. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754-758. (Pubitemid 34525533)
16. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104: 1258-1265. (Pubitemid 39166497)
17. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558-565.
18. Agathocleous A, Rule S, Johnson P, et al. Preliminary results of a phase I/II study of weekly or twice weekly borte-zomib in combination with rituximab, in patients with follicular lymphoma, mantle cell lymphoma and Waldenstrom's macroglobulinaemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110. Abstract 2559.
19. de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009;27: 5023-5030.
20. Chiappella A, Pregno P, Zinzani PL, et al. The combination of bortezomib and rituximab is effective and safe in relapsed/refractory indolent nonfollicular and mantle-cell non-Hodgkin lymphoma: a phase II multicenter study by Intergruppo Italiano Linfomi [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract 3758.
21. David KA, Smith MR, Lossos IS, et al. A phase II trial of combination bortezomib (Velcade) and rituximab for untreated "high tumor burden" indolent non-Hodgkin lymphoma (NHL) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112. Abstract 2004.
22. Di Bella N, Taetle R, Kolibaba K, et al. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010;115:475-480.
23. O'Connor OA, Portlock C, Moskowitz C, et al. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clin Cancer Res. 2010;16:719-726.
24. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112:1593-1599.
25. Kim DH, Jung HD, Kim JG, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006;108:2720-2725.
26. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940-3947. (Pubitemid 46606207)
27. Weng WK, Levy R. Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk Lymphoma. 2009;50:723-727.
28. Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood. 2004;103:1472-1474. (Pubitemid 38168664)
29. Mitrovic Z, Aurer I, Radman I, Ajdukovic R, Sertic J, Labar B. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica. 2007;92:998-999. (Pubitemid 350144253)
30. Carlotti E, Palumbo GA, Oldani E, et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica. 2007;92:1127-1130. (Pubitemid 350144222)
31. Galimberti S, Palumbo GA, Caracciolo F, et al. The efficacy of rituximab plus hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaR-IIa polymorphisms. J Chemother. 2007;19:315-321. (Pubitemid 47075128)
32. Paiva M, Marques H, Martins A, Ferreira P, Catarino R, Medeiros R. FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genet Cytogenet. 2008;183:35-40. (Pubitemid 351637610)
33. Shashidharamurthy R, Zhang F, Amano A, et al. Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fcgamma receptor CD32A. J Immunol. 2009;183:8216-8224.